Literature DB >> 21620935

Light and electron microscopic characterization of the evolution of cellular pathology in YAC128 Huntington's disease transgenic mice.

Zubeyde Bayram-Weston1, Lesley Jones, Stephen B Dunnett, Simon P Brooks.   

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disease caused by the insertion of an expanded polyglutamine sequence within the huntingtin protein. This mutation induces the formation of abnormal protein fragment aggregations and intra-nuclear neuronal inclusions in the brain. The present study aimed to produce a detailed longitudinal characterization of the neuronal pathology in the YAC128 transgenic mouse brain, to determine the similarity of this mouse model to other mouse models and the human condition in the spatial and temporal deposition pattern of the mutant protein fragments. Brain samples were taken from mice aged between 4 and 27 months of age, and assessed using S830 and GFAP immunohistochemistry, stereology and electron microscopy. Four month old mice did not exhibit intra-nuclear or extra-nuclear inclusions using the S830 antibody. Diffuse nuclear staining was present in the cortex, hippocampus and cerebellum from 6 months of age onwards. By 15 months of age, intra-nuclear inclusions were visible in most brain regions including nucleus accumbens, ventral striatum, lateral striatum, motor cortex, sensory cortex and cerebellum. The ventral striatum had a greater density of inclusions than the dorsal striatum. At 15 and 24 months of age, the mice showed increased reactive astrogliosis in the cortex, but no differences were found in the striatum. Necrotic cell death with vacuolation, uneven cell membrane and degenerated Golgi apparatus were detected ultrastructurally at 14 months of age, with some cells showing signs of apoptosis. By 26 months of age, most cells were degenerated in the transgenic animals, with lipofuscin granules being more abundant and larger in these mice than in their wildtype littermates. Our results demonstrate a progressive and widespread neuropathology in the YAC128 mice line that shares some similarity to the human condition. This article is part of a Special Issue entitled 'HD Transgenic Mouse'.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21620935     DOI: 10.1016/j.brainresbull.2011.05.005

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  12 in total

Review 1.  Age-related lysosomal dysfunction: an unrecognized roadblock for cobalamin trafficking?

Authors:  Hua Zhao; Ulf T Brunk; Brett Garner
Journal:  Cell Mol Life Sci       Date:  2011-10-21       Impact factor: 9.261

2.  HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo.

Authors:  Dagmar E Ehrnhoefer; Amber L Southwell; Meenalochani Sivasubramanian; Xiaofan Qiu; Erika B Villanueva; Yuanyun Xie; Sabine Waltl; Lisa Anderson; Anita Fazeli; Lorenzo Casal; Boguslaw Felczak; Michelle Tsang; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2018-01-15       Impact factor: 6.150

3.  Temporal Characterization of Behavioral and Hippocampal Dysfunction in the YAC128 Mouse Model of Huntington's Disease.

Authors:  Cristine de Paula Nascimento-Castro; Elisa C Winkelmann-Duarte; Gianni Mancini; Priscilla Gomes Welter; Evelini Plácido; Marcelo Farina; Joana Gil-Mohapel; Ana Lúcia S Rodrigues; Andreza Fabro de Bem; Patricia S Brocardo
Journal:  Biomedicines       Date:  2022-06-17

4.  Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease.

Authors:  Nicole M Lewandowski; Yvette Bordelon; Adam M Brickman; Sergio Angulo; Usman Khan; Jordan Muraskin; Erica Y Griffith; Paula Wasserman; Liliana Menalled; Jean Paul Vonsattel; Karen Marder; Scott A Small; Herman Moreno
Journal:  Neurobiol Dis       Date:  2012-12-04       Impact factor: 5.996

5.  Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice.

Authors:  Tristano Pancani; Daniel J Foster; Mark S Moehle; Terry Jo Bichell; Emma Bradley; Thomas M Bridges; Rebecca Klar; Mike Poslusney; Jerri M Rook; J Scott Daniels; Colleen M Niswender; Carrie K Jones; Michael R Wood; Aaron B Bowman; Craig W Lindsley; Zixiu Xiang; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-27       Impact factor: 11.205

6.  Similar striatal gene expression profiles in the striatum of the YAC128 and HdhQ150 mouse models of Huntington's disease are not reflected in mutant Huntingtin inclusion prevalence.

Authors:  Zubeyde Bayram-Weston; Timothy C Stone; Peter Giles; Linda Elliston; Nari Janghra; Gemma V Higgs; Peter A Holmans; Stephen B Dunnett; Simon P Brooks; Lesley Jones
Journal:  BMC Genomics       Date:  2015-12-21       Impact factor: 3.969

Review 7.  Mouse models of polyglutamine diseases: review and data table. Part I.

Authors:  Maciej Figiel; Wojciech J Szlachcic; Pawel M Switonski; Agnieszka Gabka; Wlodzimierz J Krzyzosiak
Journal:  Mol Neurobiol       Date:  2012-09-07       Impact factor: 5.590

8.  Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease.

Authors:  Ivan Rattray; Edward J Smith; William R Crum; Thomas A Walker; Richard Gale; Gillian P Bates; Michel Modo
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

9.  Studies on the Q175 Knock-in Model of Huntington's Disease Using Functional Imaging in Awake Mice: Evidence of Olfactory Dysfunction.

Authors:  Craig F Ferris; Praveen Kulkarni; Steven Toddes; Jason Yee; William Kenkel; Mark Nedelman
Journal:  Front Neurol       Date:  2014-06-30       Impact factor: 4.003

10.  Comparison of mHTT Antibodies in Huntington's Disease Mouse Models Reveal Specific Binding Profiles and Steady-State Ubiquitin Levels with Disease Development.

Authors:  Zubeyde Bayram-Weston; Lesley Jones; Stephen B Dunnett; Simon P Brooks
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.